Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
79 employees
APT: A clinical-stage company pioneering adaptive therapies for multi-drug resistant infections.
HQ
Founded
2016
Adaptive Phage Therapeutics (APT) is a clinical-stage company pioneering adaptive therapies for multi-drug resistant infections. APT focuses on developing treatments that evolve alongside pathogens, addressing the limitations of fixed antimicrobial therapies. The company aims to combat the growing threat of antibiotic resistance through innovative, adaptable solutions.
APT has made significant strides in the field of infectious disease treatment, leveraging its proprietary phage therapy platform. This approach has garnered attention for its potential to revolutionize how bacterial infections are treated. The company's impact is underscored by its clinical advancements and contributions to addressing global health challenges.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Phage Therapy
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
Global
When was Adaptive Phage Therapeutics founded?
Adaptive Phage Therapeutics was founded in 2016.
Where is Adaptive Phage Therapeutics's headquarters located?
Adaptive Phage Therapeutics's headquarters is located in Gaithersburg, MD, US.
When was Adaptive Phage Therapeutics's last funding round?
Adaptive Phage Therapeutics's most recent funding round was for $12M (USD) in June 2023.
How many employees does Adaptive Phage Therapeutics have?
Adaptive Phage Therapeutics has 79 employees as of Feb 5, 2024.
How much has Adaptive Phage Therapeutics raised to-date?
As of July 05, 2023, Adaptive Phage Therapeutics has raised a total of $131.7M (USD) since Jun 13, 2023.
Add Comparison
Total Raised to Date
$131.7M
USD
Last Update Jun 13, 2023
Last Deal Details
$12M
USD
Jun 13, 2023
Series B
Current Employees
79
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts